Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada

Overview of attention for article published in BMC Cancer, October 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,327 followers.

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada https://t.co/HG7FoQGBGC

30 Oct 2021

Reply Repost Favourite

New article: Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada https://t.co/BRnLo1tn5b #lungcancer #oncology https://t.co/Njgz4Ru9iz

30 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.